Kristen N Ganjoo

Publications

• Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
  Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., & Ganjoo, K. N. (2014). Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. JOURNAL OF CLINICAL ONCOLOGY, 32(29), 3299-?.
• A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study
  Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. Cw., & Helman, L. J. (2014). A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study. CANCER, 120(16), 2448-2456.
• Gastrointestinal Stromal Tumors, Version 2.2014
  von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., & Sundar, H. (2014). Gastrointestinal Stromal Tumors, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(6), 853-862.
• Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., & Sundar, H. (2014). Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(4), 473-483.
  
• A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., & George, S. (2014). A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib. ANNALS OF ONCOLOGY, 25(1), 236-240.
  
• R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K.-P., & Baker, L. H. (2011). R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. JOURNAL OF CLINICAL ONCOLOGY, 29(34), 4541-4547.
  
• Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour Ganjoo, K. N., & Patel, S. (2011). Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour. DRUGS, 71(3), 321-330.
  
• A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., & Chawla, S. P. (2011). A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. ONCOLOGY, 80(1-2), 50-56.
  
• New Developments in Targeted Therapy for Soft Tissue Sarcoma Ganjoo, K. N. (2010). New Developments in Targeted Therapy for Soft Tissue Sarcoma. CURRENT ONCOLOGY REPORTS, 12(4), 261-265.
  
• Soft Tissue Sarcoma Demetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., & Wayne, J. (2010). Soft Tissue Sarcoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(6), 630-674.
  
• NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., & Wayne, J. D. (2010). NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8, S1-S43.
  
• Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas Ganjoo, K., & Jacobs, C. (2010). Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas. CANCER, 116(5), 1177-1183.
  
• Trabectedin: an anticancer drug from the sea Ganjoo, K. N., & Patel, S. R. (2009). Trabectedin: an anticancer drug from the sea. EXPERT OPINION ON PHARMACOTHERAPY, 10(16), 2735-2743.
  
• Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec Ganjoo, K. N., Demetri, G. D., Jacobs, C., & Patel, S. (2009). Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. LEUKEMIA & LYMPHOMA, 50(11), 1882-1884.
  
• Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study. Poultsides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., & Norton, J. A. (2015). Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study. Annals of surgery, 262(4), 632-640.
  
• Combined F-18-NaF and F-18-FDG PET/CT in the Evaluation of Sarcoma Patients Jackson, T., Mosci, C., von Eyben, R., Mittra, E., Ganjoo, K., & Iagaru, A. (2015). Combined F-18-NaF and F-18-FDG PET/CT in the Evaluation of Sarcoma Patients. CLINICAL NUCLEAR MEDICINE, 40(9), 720-724.
  
• Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Guo, X., Jo, V. Y., Mills, A. M., Zhu, S. X., Lee, C.-H., & van de Rijn, M. (2015). Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical cancer research , 21(15), 3501-3511.
  
• Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report Park, M. J., Ganjoo, K. N., & Ladd, A. L. (2015). Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report. JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 40(8), 1620-1624.
  
• Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin? Worhunsky, D. J., Gupta, M., Gholami, S., Tran, T. B., Ganjoo, K. N., & Poultsides, G. A. (2015). Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin?. JOURNAL OF SURGICAL ONCOLOGY, 111(7), 808-812.
  
• Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc gamma RIIIa Patients with Previously Treated Follicular Lymphoma Ganjoo, K. N., de Vos, S., Pohlman, B. L., Flinn, I. W., Forero-Torres, A., & Wooldridge, J. E. (2015). Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc gamma RIIIa Patients with Previously Treated Follicular Lymphoma. LEUKEMIA & LYMPHOMA, 56(1), 42-48.
  
• Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study Martin-Broto, J., Cleeland, C. S., Glare, P. A., Engellau, J., Skubitz, K. M., & Atchison, C. (2014). Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. ACTA ONCOLOGICA, 53(9), 1173-1179.
  
• Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., & Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of clinical oncology , 32(17), 1797-1803.
  
• Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404) Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., & Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). LEUKEMIA & LYMPHOMA, 55(4), 768-772.
  
• The Treatment Outcome for Adult Patients with Ewing's Sarcoma Ganjoo, K. N., & Patel, S. (2013). The Treatment Outcome for Adult Patients with Ewing's Sarcoma. CURRENT ONCOLOGY REPORTS, 15(4), 372-377.
  
• Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., & Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939-942.
  
• Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., & McMillian, N. R. (2012). Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 951-960.
  
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., & Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718-720.
  
• Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., & Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231-235.
  
• Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma Forero-Torres, A., de Vos, S., Pohlman, B. L., Pashkevich, M., Cronier, D. M., & Ganjoo, K. N. (2012). Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. CLINICAL CANCER RESEARCH, 18(5), 1395-1403.
  
• The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study Ganjoo, K. N., Witten, D., Patel, M., Espinosa, I., La, T., & West, R. B. (2011). The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 34(1), 82-86.
  
• A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., & Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821-1825.
  
• TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin Hart, C. P., Borad, M., Chawla, S. P., Infante, J. R., Ganjoo, K. N., & Curd, J. G. (2010). TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin. EJC SUPPLEMENTS, 8(7), 124-124.
  
• I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., & Goris, M. L. (2010). I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. MOLECULAR IMAGING AND BIOLOGY, 12(2), 198-203.
  
• Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., & Cheson, B. D. (2010). Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study. CANCER, 116(1), 106-114.
  
• A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., & Wakelee, H. (2009). A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S674-S674.
  
• Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., & Loo, B. W. (2009). Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S939-S939.
  
• Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma Espinosa, I., Beck, A. H., Lee, C.-H., Zhu, S., Montgomery, K. D., & van de Rijn, M. (2009). Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. AMERICAN JOURNAL OF PATHOLOGY, 174(6), 2347-2356.
  
• Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., & Ganjoo, K. (2009). Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case reports in oncology, 2(3), 242-250.
  
• Breast angiosarcomas: Case series and expression of vascular endothelial growth factor Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, & Kristen Ganjoo. (2009). Breast angiosarcomas: Case series and expression of vascular endothelial growth factor. Case Reports in Oncology, 2.
  
• Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy Ganjoo, K. N., Raman, R., Sobel, R. A., & Pinto, H. A. (2009). Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy. LEUKEMIA & LYMPHOMA, 50(4), 673-675.
  
• The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients Ganjoo, K. N., Moore, A. M., Orazi, A., Sen, J. A., Johnson, C. S., & An, C. S. (2008). The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 134(3), 381-387.
  
• Review of erlotinib in the treatement of advanced non-small cell lung cancer Kristen N Ganjoo, & Heather Wakelee. (2008). Review of erlotinib in the treatement of advanced non-small cell lung cancer. Biologics; Targets & Therapy.
  
• Review of erlotinib in the treatment of advanced non-small cell lung cancer. Ganjoo, K. N., & Wakelee, H. (2007). Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : targets & therapy, 1(4), 335-346.
  
• Non-Hodgkin lymphoma of the breast Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25-30.
  
• Antiangiogenesis: A new approach to the treatment of lymphoma Ganjoo, K. (2007). Antiangiogenesis: A new approach to the treatment of lymphoma. LEUKEMIA & LYMPHOMA, 48(3), 454-455.
  
• Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., & Horning, S. J. (2006). Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. LEUKEMIA & LYMPHOMA, 47(6), 998-1005.
  
• Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia Frankel, A. E., Surendranathan, A., Black, J. H., White, A., Ganjoo, K., & Cripe, L. D. (2006). Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. CANCER, 106(10), 2158-2164.
  
• A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S. H., McClean, J., & Cripe, L. D. (2005). A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 28(2), 169-172.
  
• Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma Shafqat, A., Yum, M. N., Abanour, R., & Ganjoo, K. N. (2003). Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma. JOURNAL OF CLINICAL ONCOLOGY, 21(17), 3368-3369.
  
• Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study Schneider, B. P., Ganjoo, K. N., Seitz, D. E., Picus, J., Fata, F., & Loehrer, P. J. (2003). Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study. ONCOLOGY, 65(3), 218-223.
  
• A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study Ganjoo, K. N., GORDON, M. S., Sandler, A. B., Warner, R. E., Fife, K., & Loehrer, P. J. (2002). A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study. ONCOLOGY, 62(4), 299-304.
  
• Germ cell tumor associated primitive neuroectodermal tumors Ganjoo, K. N., Foster, R. S., Michael, H., Donohue, J. P., & Einhorn, L. H. (2001). Germ cell tumor associated primitive neuroectodermal tumors. JOURNAL OF UROLOGY, 165(5), 1514-1516.
  
• Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K., & Einhorn, L. H. (2000). Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. CANCER, 88(5), 1051-1056.
  
• Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma Ganjoo, K. N., Chan, R. J., Sharma, M., & Einhorn, L. H. (1999). Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. JOURNAL OF CLINICAL ONCOLOGY, 17(11), 3457-3460.
  
• Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. S., & Brown, J. W. (1999). Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 118(4), 692-700.
  
• Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella Ganjoo, K. N., Loyal, J. A., Cramer, H. M., & Loehrer, P. J. (1999). Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella. JOURNAL OF CLINICAL ONCOLOGY, 17(9), 2995-2997.